Diligence memo · auto-generated · as of July 2, 2026
Tempest Therapeutics, Inc.
Tempest Therapeutics, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Tempest Therapeutics, Inc. operates in Biotechnology, based in South San Francisco.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Tempest Therapeutics, Inc. has raised $180M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $83M on 2018-02-16.
Most recent recorded round closed around 2022-04-26.
Valuation (modeled)modeled
Provath models Tempest Therapeutics, Inc. at approximately $307M (range $46M–$631M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.62× the median modeled value of Series C Biotechnology companies in 2022–2024 (111 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 13 months.
Last raise 4.2 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 5.5× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 96% of Biotechnology peers (4293 compared).
Modeled value ranks above 77% of those peers.
Closest niche peers: Dianthus Therapeutics, Inc., Satellite Biosciences, Inc., Deepcell, Inc., Ventus Therapeutics U.S., Inc., Morphic Holding, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.